Cytek Biosciences Inc Revenue Growth Rates (CTKB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cytek Biosciences Inc   (NASDAQ: CTKB)
 

CTKB's Revenue Growth by Quarter and Year

Cytek Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CTKB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 48.14
1st Quarter March 43.25
FY 91.39

CTKBs Annual Revenue
Cytek Biosciences Inc 's Revenue in the fiscal year 2025 $ 201.46 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2024 $ 200.11 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2023 $ 192.43 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2022 $ 164.04 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2021 $ 127.95 millions




CTKB Revenue second quarter 2026 Y/Y Growth Comment
Cytek Biosciences Inc reported Revenue growth of 5.57% year on year in the second quarter 2026, to $ 48.14 millions, this is lower than Cytek Biosciences Inc 's recent average Revenue increase of 14.19%.

Looking into second quarter 2026 results within Laboratory Analytical Instruments industry 16 other companies have achieved higher Revenue growth. While Cytek Biosciences Inc ' s Revenue increase of 5.57% ranks overall at the positon no. 2628 in the second quarter 2026.


CTKB Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 5.95 % -0.59 % 22.05 %
3rd Quarter September - 1.06 % 8.12 % 16.55 %
2nd Quarter June 5.57 % -1.81 % -5.53 % 22.41 %
1st Quarter March 5.08 % -6.48 % 18.66 % 5.79 %
FY   - 0.17 % 3.99 % -

Financial Statements
Cytek Biosciences Inc 's second quarter 2026 Revenue $ 48.14 millions CTKB's Income Statement
Cytek Biosciences Inc 's second quarter 2025 Revenue $ 45.60 millions Quarterly CTKB's Income Statement


CTKB Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 20.54 % 14.98 % 25.05 %
3rd Quarter September - 13.05 % 9.84 % -4.03 %
2nd Quarter June 11.31 % 10.79 % 5.52 % 32.54 %
1st Quarter March -30.4 % -29.82 % -25.41 % -23.27 %
FY (Year on Year)   - 0.17 % 3.99 % -


Back to CTKB Growth rate Comparisons >> Back to CTKB Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #17
Healthcare Sector #381
Overall #2628

Revenue Y/Y Growth Statistics
High Average Low
39.97 % 14.19 % -1.74 %
(Mar 31 2022)  
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #17
Healthcare Sector #381
Overall #2628
Revenue Y/Y Growth Statistics
High Average Low
39.97 % 14.19 % -1.74 %
(Mar 31 2022)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cytek Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
32.56 % 5.81 % -30.39 %
(Jun 30 2023)  


CTKB's II. Quarter Q/Q Revenue Comment
Cytek Biosciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 11.31%, to $ 48.14 millions, from $43.25 millions in the first quarter.
CTKB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Cytek Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 763.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #123
Overall #763
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #123
Overall #763
Revenue Q/Q Growth Statistics
High Average Low
32.56 % 5.81 % -30.39 %
(Jun 30 2023)  


CTKB's II. Quarter Q/Q Revenue Comment
Cytek Biosciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 11.31%, to $ 48.14 millions, from $43.25 millions in the first quarter.
CTKB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Cytek Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 763.


Cytek Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 205.09 $ 202.55 $ 200.45 $ 196.96 $ 196.42
Y / Y Revenue Growth (TTM) 4.41 % 2.69 % 0.17 % -1.74 % -0.11 %
Year on Year Revenue Growth Overall Ranking # 2369 # 2976 # 2698 # 2492 # 2553
Seqeuential Revenue Change (TTM) 1.25 % 1.05 % 1.77 % 0.28 % -0.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 2369 # 2976 # 2698 # 2492 # 2553


Cumulative Revenue growth Comment
Although Cytek Biosciences Inc 's Annual Revenue growth year on year were below company's average 14.19% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.41% year on year, from 2.69% in Mar 31 2026.

In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2369, from total ranking in previous quarter at 2976.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 379
Overall # 2647

Revenue TTM Y/Y Growth Statistics
High Average Low
39.97 %
 14.19 %
-1.74 %
(Mar 31 2022)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 381
S&P 500 # 2671
Cumulative Revenue growth Comment
Although Cytek Biosciences Inc 's Annual Revenue growth year on year were below company's average 14.19% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.41% year on year, from 2.69% in Mar 31 2026.

In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2369, from total ranking in previous quarter at 2976.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 379
Overall # 2647

Revenue TTM Y/Y Growth Statistics
High Average Low
39.97 %
14.19 %
-1.74 %
(Mar 31 2022)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 381
S&P 500 # 2671




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CTKB's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions
Electromed Inc 8.97%$ 8.968 millions
National Healthcare Corp8.83%$ 8.833 millions
Chemed Corporation8.80%$ 8.800 millions
Tactile Systems Technology Inc 8.76%$ 8.763 millions
Gyre Therapeutics Inc 8.72%$ 8.718 millions
P3 Health Partners Inc 8.60%$ 8.599 millions
Maravai Lifesciences Holdings Inc 8.53%$ 8.534 millions
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions
Addus Homecare Corp8.18%$ 8.181 millions
Puma Biotechnology Inc 7.75%$ 7.754 millions
Cryoport inc 7.74%$ 7.737 millions
Schrodinger Inc 7.54%$ 7.542 millions


About Cytek Biosciences Inc Revenue Growth Rates (CTKB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cytek Biosciences Inc (CIK 1831915).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-053496
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cytek Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.